CEFOTAXIME SODIUM

Search structure
Trade Names:
Synonyms:
Status: Approved (1981)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 258J72S7TZ
Parent Compound: CEFOTAXIME

Structure
InChI Key AZZMGZXNTDTSME-JUZDKLSSSA-M
Smile CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(C)=O)CS[C@H]12)c1csc(N)n1.[Na+]
InChI
InChI=1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H16N5NaO7S2
Molecular Weight 477.46
AlogP -0.62
Hydrogen Bond Acceptor 11.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 173.51
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial penicillin-binding protein inhibitor PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 104
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
- 24000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

Scaffolds

Parent

Side Effects from Label

Side effects Relative Frequency (%) Labels
Immune system disorders Hypersensitivity 2.4

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
12.18
General disorders and administration site conditions
10.85
Investigations
9.94
Vascular disorders
8.04
Infections and infestations
7.4
Immune system disorders
7.27
Gastrointestinal disorders
6.66
Nervous system disorders
6.39
Blood and lymphatic system disorders
5.22
Cardiac disorders
5.22
Respiratory, thoracic and mediastinal disorders
5.2
Injury, poisoning and procedural complications
3.75
Metabolism and nutrition disorders
2.47
Hepatobiliary disorders
2.4

Cross References

Resources Reference
ChEBI 3498
ChEMBL CHEMBL1010
FDA SRS 258J72S7TZ
KEGG C08113
PubChem 10695961
SureChEMBL SCHEMBL41092
CONTENTS